Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan

Published: Thursday, January 30, 2014
Last Updated: Thursday, January 30, 2014
Bookmark and Share
Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines.

Horizon Discovery™ announce that it has entered into a large-scale licensing agreement with a Japanese medical university. The agreement covers a limited use label license for academic use of 250 of Horizon’s X-MAN™ genetically defined, isogenic cell lines, and demonstrates the global recognition of the company’s in vitro disease models.

Horizon’s X-MAN isogenic cell lines accurately model the disease-causing mutations found in patients with cancer, and increasingly other diseases. Horizon creates these cell lines using its precision genome-editing GENESIS™ platform, consisting of rAAV, ZFN and CRISPR technologies, to engineer specific disease-related mutations. These models help researchers understand how complex genetic diseases manifest themselves in patients, and can reduce the cost of bringing to market new personalized therapies by streamlining many aspects of drug development including target identification, target validation, assay development, drug screening, lead optimization, and biomarker-driven clinical trial design.

Kam Dhaliwal, VP Sales, Horizon Discovery, commented: “This is a very significant deal for Horizon Discovery, covering a large number of cell lines and representing a large investment by the university. We are delighted that our distribution partnership in Japan with Summit Pharmaceuticals International (SPI) is proving so productive.  Summit has proven to be extremely effective in opening the Japanese market for Horizon and we anticipate further adoption of our products and services in Japan in the future.”

The director of the Translational Research Centre at the university commented: “Horizon’s X-MAN cell lines offer a unique and valuable resource for the study of specific, disease-related mutations. We are look forward to applying the X-MAN technology in our research projects.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon, Fulcrum Launch Collaboration
Horizon Discovery and Fulcrum Therapeutics form collaboration for novel CRISPR-based target discovery in genetic diseases.
Tuesday, September 06, 2016
Wistar, Horizon Ink Exclusive License Deal
The Wistar Institute has granted Horizon Discovery an exclusive license to 153 of its Melanoma Patient-Derived Xenograft models.
Thursday, July 21, 2016
Horizon, Centauri Therapeutics Launch Collaboration
Joint venture creates a differentiated new player in the rapidly growing immuno-oncology market, currently valued at £25 billion.
Thursday, March 03, 2016
Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Discovery & Thermo Agreement
Horizon Discovery Group plc and Thermo Fisher Scientific sign supply and commercialization agreement, which will see Thermo market and distribute Horizon’s X-MAN cell line collection.
Monday, April 20, 2015
Horizon and Partners Awarded Up to £6.2M Funding
Horizon to receive up to £652,000 to expand bioproduction research.
Thursday, March 26, 2015
Horizon Discovery Group plc Named Business of the Year at Business Weekly Awards
Horizon joins select group of companies to receive award for a second time.
Wednesday, March 18, 2015
Horizon Discovery Group Selected as Core Facility by Tri-Institutional Therapeutics Discovery Institute
Two year master services agreement signed with an initial work order for $500,000 to carry out drug combination screening and in vitro assay development.
Monday, February 02, 2015
Horizon Discovery Group plc Trading Update
Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering.
Monday, January 19, 2015
Horizon Discovery CEO Wins Executive of the Year
Darrin Disley wins Executive of the Year award at the SCRIP Awards.
Thursday, December 04, 2014
Horizon Discovery Group plc and Adarza BioSystems Enter Supply & Licensing Agreement
Agreement gives Horizon exclusive right to supply services on Adarza’s multiplex label-free immunoassay technology.
Monday, November 24, 2014
Horizon Discovery Group Signs Agreement with Top Ten Pharma Company for Approximately $750,000
Horizon CombinatoRx to perform drug combination screening on a lead oncology asset.
Monday, November 17, 2014
Horizon Discovery Collaborate with Top Ten Pharma Company
Horizon CombinatoRx to perform drug combination screening on lead oncology asset.
Wednesday, October 15, 2014
Horizon and OPDC Sign Collaboration Agreement
Horizon CombinatoRx to perform in-vitro cell line screening of OPDC clinical stage development candidates.
Friday, July 25, 2014
Horizon Completes Acquisition of CombinatoRx from Zalicus
Acquisition of revenue generating and complementary business establishes Horizon’s headquarters in North America.
Monday, June 02, 2014
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
Ribosome Recycling as a Drug Target
Researchers explain mechanism that recycles bacterial ribosomes stalled on messenger RNAs that lack termination codons.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Cancer Signaling Pathway Illuminating Way To Therapy
Researchers refine a pro-growth signalling pathway, common to cancers, that can kill cancer cells while leaving healthy cells unharmed.
Toxoplasma’s Balancing Act Explained
Parasite’s method of rewiring our immune response leads to novel tool for drug tests.
T Cell Channel Could Be Targeted to Treat Cancers
Researcher identify ion-channel found within T cells that could be targeted to reduce development of neck and head cancers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!